An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.

Inclusion Criteria: * \>/= 18 years old * Enrolled in the UPMC insurance plan for at least 1 year * Identified by UPMC Healthplan as a Pitt/UPMC employee who is likely to benefit from preemptive PGx panel testing based on polypharmacy, high annual prescription costs and a risk for poor medication-related outcomes based on exposure to medications with FDA or CPIC Level A/B PGx guidance using payer data * Participating in Pitt+Me Discovery with elective return of PGx results Exclusion Criteria: * Previous panel PGx testing (self-reported) * Have a terminal illness (specifically metastatic cancer, palliative care or hospice) * Have had a liver, small bowel, or allogenic bone marrow/stem cell transplant * Cannot provide informed consent and/or complete the study protocol due to serious cognitive impairment * Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing home facility) * Plan to drop UPMC Health Plan coverage for any reason within 12 months of enrollment * Recent blood transfusion may be exclusionary only if the end of recruitment is nearing and there is insufficient time to observe a minimum waiting period between date of transfusion and date of sample collection. These minimum waiting periods are determined by type of transfusion: 7 days for platelets/plasma/cryoprecipitate; 2 months for packed red blood cells (PRBCs): and 6 months for whole blood or unknown type of transfusion. Although a transfusion is unlikely to have major effects …